| Company | Date | Position | Consensus ⓘ | Price Target ⓘ | 2-Yr Return |
|---|---|---|---|---|---|
|
VOR
Vor Biopharma
|
Mar 29, 2026 | BUY |
Buy
+199.3% avg upside
17 analysts
|
$50.00
245.16% Upside
|
-4.3% |
|
RLMD
Relmada Therapeutics
|
Dec 21, 2025 | BUY |
Buy
+106.4% avg upside
15 analysts
|
$9.00
33.70% Upside
|
+42.0% |
|
VERA
Vera Therapeutics
|
Nov 26, 2025 | BUY |
Strong Buy
+91.0% avg upside
19 analysts
|
$45.00
28.33% Upside
|
-3.1% |
|
RIGL
Rigel
|
Nov 05, 2025 | BUY |
Strong Buy
-27.5% avg upside
17 analysts
|
$42.00
27.70% Upside
|
-13.6% |
|
NUVB
Nuvation Bio
|
Sep 29, 2025 | BUY |
Strong Buy
+132.2% avg upside
15 analysts
|
$10.00
79.80% Upside
|
+65.5% |
|
HOWL
Werewolf Therapeutics
|
Aug 04, 2025 | BUY |
Strong Buy
+1871.3% avg upside
8 analysts
|
$4.00
1038.70% Upside
|
-72.3% |
|
PYXS
Pyxis Oncology
|
Mar 18, 2025 | BUY |
Strong Buy
+244.6% avg upside
13 analysts
|
$6.00
195.63% Upside
|
+79.2% |
Disclaimer: 13Foresight compiles analyst ratings and price targets from publicly available sources. Performance metrics, rankings and star ratings shown here are calculated independently by 13Foresight from historical market prices and may differ from figures published elsewhere. This information may be incomplete, delayed or inaccurate, is provided for research and informational purposes only, and is not investment advice. The underlying ratings and opinions are those of the respective analysts and their firms; 13Foresight accepts no liability for any decisions made based on this data.